Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

JCO Clin Cancer Inform

Laurent Dercle, Binsheng Zhao, and Lawrence H. Schwartz, Columbia University Medical Center and New York Presbyterian Hospital; Mithat Gönen, Patrick Hilden, and Chaya S. Moskowitz, Memorial Sloan Kettering Cancer Center, New York, NY; Dana E. Connors and Stacey J. Adam, Foundation for the National Institutes of Health, North Bethesda, MD; Ying Tang, CCS Associates, San Jose, CA; Sanja Karovic and Michael Maitland, Inova Schar Cancer Institute, Fairfax, VA; Gary Kelloff, National Cancer Institute, Rockville, MD; and Geoffrey R. Oxnard, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

Published: December 2018

Purpose: To develop a public-private partnership to study the feasibility of a new approach in collecting and analyzing clinically annotated imaging data from landmark phase III trials in advanced solid tumors.

Patients And Methods: The collection of clinical trials fulfilled the following inclusion criteria: completed randomized trials of > 300 patients, highly measurable solid tumors (non-small-cell lung cancer, colorectal cancer, renal cell cancer, and melanoma), and required sponsor and institutional review board sign-offs. The new approach in analyzing computed tomography scans was to transfer to an academic image analysis laboratory, draw contours semi-automatically by using in-house-developed algorithms integrated into the open source imaging platform Weasis, and perform serial volumetric measurement.

Results: The median duration of contracting with five sponsors was 12 months. Ten trials in 7,085 patients that covered 12 treatment regimens across 20 trial arms were collected. To date, four trials in 3,954 patients were analyzed. Source imaging data were transferred to the academic core from 97% of trial patients (n = 3,837). Tumor imaging measurements were extracted from 82% of transferred computed tomography scans (n = 3,162). Causes of extraction failure were nonmeasurable disease (n = 392), single imaging time point (n = 224), and secondary captured images (n = 59). Overall, clinically annotated imaging data were extracted in 79% of patients (n = 3,055), and the primary trial end point analysis in each trial remained representative of each original trial end point.

Conclusion: The sharing and analysis of source imaging data from large randomized trials is feasible and offer a rich and reusable, but largely untapped, resource for future research on novel trial-level response and progression imaging metrics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873999PMC
http://dx.doi.org/10.1200/CCI.17.00137DOI Listing

Publication Analysis

Top Keywords

imaging data
16
source imaging
12
imaging
9
public-private partnership
8
clinically annotated
8
annotated imaging
8
randomized trials
8
computed tomography
8
tomography scans
8
trial
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!